Show simple item record

dc.contributor.authorZwart LL de
dc.contributor.authorHaenen HEMG
dc.contributor.authorVersantvoort CHM
dc.contributor.authorSips AJAM
dc.date.accessioned2012-12-12T18:28:52Z
dc.date.available2012-12-12T18:28:52Z
dc.date.issued2002-06-28
dc.identifier623860011
dc.identifier.urihttp://hdl.handle.net/10029/259348
dc.description.abstractAbstract niet beschikbaar
dc.description.abstractBoth in the development of medicinal products as well as in risk assessment of other xenobiotics there is an increasing awareness that children should be considered as a special group. Children are exposed to other doses than adults and the pharmacokinetics and pharmacodynamics can be very different in children and adults. In general it can be concluded that the effects of age on pharmacokinetics are most pronounced during the first 6-12 months of life. Full adjustment of dosing or TDI's for pharmacokinetic differences can relatively easily be applied and should, to our opinion be seen as a first step in considering risk for the paediatric population. For risk assessment for drugs as well as for other xenobiotics, it seems to be essential that young animal models will be used for determining NOAELs, that are relevant for the paediatric population. The use of a paediatric PBPK model possibly combined with pharmacodynamics (PBPK/PD model) may be a valuable aid in risk assessment.
dc.description.sponsorshipVWS; directie GZB
dc.formatapplication/pdf
dc.format.extent69 p
dc.format.extent1411 kb
dc.language.isoen
dc.relation.ispartofRIVM rapport 623860011
dc.relation.urlhttp://www.rivm.nl/bibliotheek/rapporten/623860011.html
dc.relation.urlhttp://www.rivm.nl/bibliotheek/rapporten/623860011.pdf
dc.subject02nl
dc.subjectrisk assessmenten
dc.subjectpharmacokineticsen
dc.subjectchildrenen
dc.titlePharmacokinetics of ingested xenobiotics in children: A comparison with adultsen
dc.title.alternativeFarmacokinetiek van orale xenobiotica in kinderen: Een vergelijking met volwassenennl
dc.typeOnderzoeksrapport
dc.contributor.departmentLBV
dc.date.updated2012-12-12T18:28:53Z
html.description.abstractAbstract niet beschikbaar
html.description.abstractBoth in the development of medicinal products as well as in risk assessment of other xenobiotics there is an increasing awareness that children should be considered as a special group. Children are exposed to other doses than adults and the pharmacokinetics and pharmacodynamics can be very different in children and adults. In general it can be concluded that the effects of age on pharmacokinetics are most pronounced during the first 6-12 months of life. Full adjustment of dosing or TDI's for pharmacokinetic differences can relatively easily be applied and should, to our opinion be seen as a first step in considering risk for the paediatric population. For risk assessment for drugs as well as for other xenobiotics, it seems to be essential that young animal models will be used for determining NOAELs, that are relevant for the paediatric population. The use of a paediatric PBPK model possibly combined with pharmacodynamics (PBPK/PD model) may be a valuable aid in risk assessment.


This item appears in the following Collection(s)

Show simple item record